• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PhRMA: More than 100 medicines for mental health disorders in development

PhRMA: More than 100 medicines for mental health disorders in development

May 7, 2014
CenterWatch Staff

America’s biopharmaceutical research companies currently are developing 119 novel new medicines to help improve the lives of the estimated 61.5 million Americans affected by mental health disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

These medicines in development—all either in clinical trials or under review by the FDA—include 36 for schizophrenia, 29 for depression, 20 for substance/addictive disorders, 15 for attention deficit/hyperactivity disorder and 15 for anxiety disorders.

Mental health conditions pose a heavy human and economic burden in the U.S. According to the National Institute of Mental Health (NIMH), one in four American adults has been diagnosed with a mental health disorder, and serious mental illnesses cost the U.S. more than $317 billion annually in lost wages, healthcare expenditures and disability benefits.

“As our knowledge of the brain continues to expand, biopharmaceutical scientists are finding new, exciting ways to help patients facing depression, schizophrenia and many other disorders,” said John J. Castellani, PhRMA president and CEO. “The more than 100 medicines in development today represent tremendous hope for patients, our healthcare system and our economy.”

Sponsors, working in collaboration with academia, government researchers, patient organizations and others in the innovation ecosystem, are applying new scientific approaches and evolving knowledge of disease to bring new solutions to patients.

The array of innovative approaches being pursued includes:

  • A medicine that may provide a broader spectrum of therapeutic activity for attention-deficit/hyperactivity disorder (ADHD)
  • An intranasal medicine for treatment-resistant depression that may offer  a rapid onset of therapeutic effects
  • A medicine for schizophrenia that potentially could result in fewer negative side effects than existing treatments.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing